TalkMed Group (SGX:5G3) EBIT : S$38.17 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is TalkMed Group EBIT?

TalkMed Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was S$21.60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was S$38.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TalkMed Group's annualized ROC % for the quarter that ended in Dec. 2023 was 134.14%. TalkMed Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 433.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TalkMed Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 8.36%.

TalkMed Group EBIT Historical Data

The historical data trend for TalkMed Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TalkMed Group EBIT Chart

TalkMed Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

41.74

25.33

27.68

37.19

38.17

TalkMed Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															14.92	14.80	22.40	16.57	21.60

Competitive Comparison of TalkMed Group's EBIT

For the Medical Care Facilities subindustry, TalkMed Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TalkMed Group's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TalkMed Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TalkMed Group's EV-to-EBIT falls into.

TalkMed Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$38.17 Mil.

TalkMed Group (SGX:5G3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TalkMed Group's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	43.998 * ( 1 - 21.21% )	/	( (23.984	+	27.702)	/ 2 )
=	34.6660242	/	25.843
=	134.14 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	105.776	-	12.385	-	( 81.588	-	max(0, 23.023	-	92.43	+	81.588	))
=	23.984

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	115.786	-	12.264	-	( 89.896	-	max(0, 27.278	-	103.098	+	89.896	))
=	27.702

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

TalkMed Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	43.204	/	( ( (10.277 + max(-10.305, 0))	+	(9.661 + max(-9.692, 0)) )	/	2 )
=	43.204	/	( ( 10.277	+	9.661 )	/	2 )
=	43.204	/	9.969
=	433.38 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(9.323	+	1.208	+	0.31100000000001)	-	(12.385	+	0	+	8.762)
=	-10.305

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(10.572	+	1.424	+	0.863)	-	(12.264	+	0	+	10.287)
=	-9.692

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TalkMed Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	38.172	/	456.580
	=	8.36 %

TalkMed Group EBIT Related Terms

Thank you for viewing the detailed overview of TalkMed Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

TalkMed Group (SGX:5G3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TalkMed Group Ltd (SGX:5G3) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Mount Elizabeth, Mount Elizabeth Hospital Level 2, Singapore, SGP, 228510

Website

https://www.talkmed.com.sg

TalkMed Group Ltd operates as an investment holding company. It is a provider of medical oncology, stem cell transplants and palliative care services, serving patients in Singapore and the region. Outside Singapore, the Group operates in Vietnam, Hong Kong and the People's Republic of China. The activities of the company are the provision of medical oncology services and palliative care healthcare services in Singapore. It is organized into three reportable operating segments, Oncology Services, Stem Cells Services and Cellular and gene therapy-related products and services. The company has operational footprints across Singapore, Hong Kong and Vietnam of which Singapore contributes the vast majority of total revenue. It generates maximum revenue from the Oncology services segment.

TalkMed Group (SGX:5G3) Headlines

No Headlines